

Jubilant plans to raise ₹2,000 cr through NCDs

PRESS TRUST OF INDIA

New Delhi

DRUG firm Jubilant Life Sciences on Tuesday said its shareholders have approved raising Rs 2,000 crore through redeemable non-convertible debentures (NCDs) on a private placement basis or rights basis in one or more tranches.

In a BSE filing, the company said its shareholders have authorised the board to offer or invite subscriptions for secured or unsecured redeemable non-convertible debentures, in one or more series or tranches, aggregating up to Rs 2,000 crore on private placement basis or rights basis.

The company added that the borrowing through debentures will be within the above overall borrowing limit of Rs 5,000 crore.

Jubilant Life Sciences is engaged in manufacture and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy prod-



Fund raising

■ Shareholders authorised subscriptions for debentures up to Rs 2,000 crore on private placement basis or rights basis

■ The company added that the borrowing through debentures will be within the overall borrowing limit of Rs 5,000 crore

ucts and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.

JUBILANT LIFE/BSE Rs 175.90 ▲

NSE Rs 175.70 ▲

Company